BULLFROG AI HOLDINGS INC C/WTS EXP (TO PUR COM) News

Join BullFrog AI's Exclusive Live Investor Webinar and Q&A Session on June 12

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intellige

GlobeNewswireMay 29 08:00 ET

Express News | Bullfrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders

ReutersMay 16 08:00 ET

10-Q: Quarterly report

SEC announcementMay 10 16:09 ET · Announcements

BullFrog AI's CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo

GAITHERSBURG, Md., April 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificia

GlobeNewswireApr 9 08:00 ET

CEO and 10% Owner Vininder Singh Sells 50,000 Shares of Bullfrog AI Holdings Inc (BFRG)

Yahoo FinanceApr 4 01:31 ET

Form 144 | BullFrog AI(BFRG.US) Insider Proposes to Sell 755K in Common Stocks

SEC FILLINGS DISCLOSED/ Apr 3, $BULLFROG AI HOLDINGS INC C/WTS EXP (TO PUR COM)(BFRGW.US)$、$BullFrog AI(BFRG.US)$、$BullFrog AI Holdings(BFAI.US)$ Insider Vininder Singh intends to sell 250K shares of

moomoo NewsApr 3 09:07 ET

BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute

GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireMar 8 08:00 ET

BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer

GAITHERSBURG, Md., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireFeb 26 08:00 ET

BullFrog AI Announces Underwriter's Decision to Exercise Over-Allotment Option to Purchase 218,382 Shares of the Company's Common Stock

GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI)

GlobeNewswireFeb 21 12:01 ET

BullFrog AI to Discuss Findings From Its Collaboration With Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

GAITHERSBURG, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireFeb 9 08:00 ET

BullFrog AI Announces Closing of $5.7 Million Public Offering

GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireFeb 5 10:00 ET

Bullfrog AI Announces Pricing of $5.7 Million Public Offering

GAITHERSBURG, Md., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireFeb 1 09:00 ET

BullFrog AI Strengthens Scientific Advisory Board With the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala

GAITHERSBURG, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireJan 26 07:30 ET

BullFrog AI's Collaboration With Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

GAITHERSBURG, Md., Jan. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireJan 17 07:00 ET

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

Issued patent provides protection for BF-223 and related compoundsGAITHERSBURG, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company

GlobeNewswireJan 16 08:00 ET

BullFrog AI Issues Letter to Shareholders

GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireDec 29, 2023 08:00 ET

BullFrog AI Launches Preclinical Study to Investigate BF-114's Potential in Battling Obesity

The market for obesity drugs is projected to exceed $77 billion by 2030 Dr. Randy Seeley, a recognized expert on novel treatments for obesity, to lead study GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) --

GlobeNewswireDec 6, 2023 07:00 ET

BullFrog AI to Present at Benzinga All Access Event on October 20

GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireOct 18, 2023 09:00 ET

BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven BfLEAP Platform

Discoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP platform Target validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a world-leading

GlobeNewswireOct 5, 2023 08:00 ET

BullFrog AI Announces Positive Data From Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma

GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial

GlobeNewswireSep 26, 2023 08:00 ET